Yes, donepezil is very likely causing her diarrhea and should be discontinued immediately.
Diarrhea is one of the most common adverse effects of donepezil, occurring in approximately 10% of patients on 5 mg daily, and the temporal relationship in this case strongly implicates the medication. 1
Why Donepezil is the Culprit
The FDA drug label clearly identifies diarrhea as a cholinomimetic effect of donepezil that occurs at twice the rate of placebo. In clinical trials:
- 10% of patients on donepezil 5 mg developed diarrhea versus 5% on placebo 1
- Diarrhea was significant enough to cause discontinuation in 3% of patients on the 10 mg dose 1
- These gastrointestinal effects are dose-related and can persist or worsen over time 1
The timeline in this patient is classic: she started donepezil 4 months ago, developed intermittent diarrhea at 2 months (suggesting cumulative cholinergic effects), and now has worsening symptoms with all loose stools for 2 weeks. This progressive pattern is consistent with donepezil's mechanism of increasing acetylcholine activity in the gut.
Important Clinical Considerations
The patient's age (81 years) increases her risk - the FDA label specifically notes that adverse reactions occur more frequently with advancing age 1. Prolonged diarrhea in an elderly patient carries serious risks:
- Dehydration and electrolyte disturbances
- Hypokalemia (a rare but documented complication of donepezil-induced diarrhea) 2
- Falls and functional decline
- Potential cardiac complications if electrolytes become severely deranged 3, 4
Management Algorithm
- Discontinue donepezil immediately - she has already stopped it, which is appropriate
- Monitor for symptom resolution - diarrhea should improve within days to 1-2 weeks after stopping
- Check electrolytes (particularly potassium) given the duration and severity of diarrhea
- Ensure adequate hydration during recovery
- If diarrhea persists beyond 1-2 weeks after stopping donepezil, investigate other causes
Alternative Treatment Options
If cognitive treatment is still desired after GI symptoms resolve:
- Consider a transdermal donepezil patch - recent evidence shows significantly fewer GI side effects compared to oral formulations while maintaining therapeutic efficacy 5, 6
- Try memantine instead - has a different mechanism (NMDA antagonist) with lower rates of GI side effects 7
- Consider galantamine or rivastigmine - though these also carry GI risks as cholinesterase inhibitors 7
Common Pitfall to Avoid
Do not restart oral donepezil at the same or higher dose. The FDA label notes that adverse reactions were often transient in trials, but this patient's worsening symptoms over 2 months indicate she is not tolerating the medication. If restarting is considered, only do so with the transdermal formulation or after switching to a different drug class entirely.
The fact that she thought to stop the medication herself and did so yesterday was clinically appropriate given her symptom severity.